{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-216798","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2022-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.046929+00:00","generated_at":"2026-06-24T01:31:39.575382+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cullinan Oncology reports Q2 2022 net income of $174.1M, cash runway through 2026 after Taiho deal","bullets":["Cash and investments $656M as of June 30, 2022; expected to fund operations through 2026.","Completed strategic collaboration with Taiho for CLN-081; received $275M upfront, eligible for $130M milestones.","Net income of $174.1M in Q2 2022 vs net loss of $12.9M in Q1 2022, driven by $276.8M gain on sale of Cullinan Pearl.","Updated CLN-081 data at ASCO: median DOR >21 months, median PFS 12 months, 41% confirmed ORR at 100mg BID.","Initial clinical data for CLN-619 and CLN-049 expected by mid-2023; IND filings for CLN-617, CLN-978 in H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-216798","json":"https://secwatch.observer/filing/0001193125-22-216798.json","markdown":"https://secwatch.observer/filing/0001193125-22-216798.md","text":"https://secwatch.observer/filing/0001193125-22-216798.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000119312522216798/0001193125-22-216798-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000119312522216798/d369450d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:31:39.575382+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}